Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). Issue 2 (4th December 2017) - Godet, Sophie; Protin, Caroline; Dupuis, Jehan; Dartigeas, Caroline; Bastie, Jean‐Noël; Herbaux, Charles; Leblond, Véronique; de Guibert, Sophie; Ghez, David; Brion, Annie; Ysebaert, Loïc; Delmer, Alain; et al.